Seattle Genetics Presents Clinical Trials Data at ASCO Annual Meeting

Seattle Genetics, Inc. introduced that in fact data from a number of clinical trials of ADCETRIS will be introduced at the 2012 American Society of Clinical Oncology (ASCO) Yearly Gathering being held June 1-5, 2012 in Chicago, IL. Data show the undertaking and tolerability whenever affected individuals are retreated by using ADCETRIS, the undertaking and tolerability of ADCETRIS in CD30-positive non-Hodgkin lymphomas and CD30 term using a screening process in non-lymphoma malignancies. ADCETRIS is definitely an antibody-drug conjugate (ADC) instructed to CD30.

"Our desire is good for ADCETRIS to get the basics of therapy for CD30-positive malignancies and, to achieve this, we are aggressively possessing its clinical progress and exactly discovering CD30 expression across countless cancer types," said Clay B. Siegall, Ph.D., President and Chief Executive Officer of Seattle Genetics. "Our facts shows at ASCO highlight the possible for ADCETRIS and strengthen our progress strategy to generate facts which will support stepwise development of ADCETRIS for affected individuals with CD30-expressing malignancies."